A recombinant human interleukin-1 beta protects adriamycin-induced toxicity. Adriamycin cardiotoxicity and interleukin-1.
Pretreatment with recombinant human interleukin-1 beta (IL-1) protected normal BALB/c mice from the lethal effect adriamycin (ADM) of related to dose and frequency of administration. Posttreatment with IL-1 failed to protect. Neutrophil and platelet counts after the administration of ADM (16 mg/kg) did not differ between the group with and that without IL-1 pretreatment, whereas lipid peroxide levels in the heart were reduced in the group pretreated with IL-1. It appears that the chemoprotection mechanism of IL-1 lies in the prevention of cardiotoxicity due to ADM-induced free radicals.
Okumura
H
H
Department of Internal Medicine, Toyama Prefectural Central Hospital, Japan.
Yoshida
T
T
Kaya
H
H
Matano
S
S
Okabe
Y
Y
Ohtake
S
S
Nakamura
S
S
Matsuda
T
T
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity*; D006321:Heart / Q000187:drug effects*; D007375:Interleukin-1 / Q000494:pharmacology*; D007958:Leukocyte Count / Q000187:drug effects; D008054:Lipid Peroxides / Q000032:analysis; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011994:Recombinant Proteins / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000096:biosynthesis
D007375:Interleukin-1; D008054:Lipid Peroxides; D011994:Recombinant Proteins; D004317:Doxorubicin; D013482:Superoxide Dismutase